MFDS — authorised 23 March 2022
- Marketing authorisation holder: AAA USA NOVARTIS
- Status: likely_approved
🇰🇷 Pluvicto in South Korea
MFDS authorised Pluvicto on 23 March 2022
Marketing authorisation
Pluvicto in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in South Korea
Frequently asked questions
Is Pluvicto approved in South Korea?
Yes. MFDS authorised it on 23 March 2022.
Who is the marketing authorisation holder for Pluvicto in South Korea?
AAA USA NOVARTIS holds the South Korean marketing authorisation.